{"cursor":"38712","size":15,"audio":[],"currentlang":"en","article":"{{Drugbox\n\n\n| Verifiedfields = changed verifiedrevid = 477165031 type = mab mab_type = mab\n| source = zu/o target = VEGF-A\n\n\n| tradename = Avastin Drugs.com = licence_EU = Avastin licence_US = Bevacizumab\n| pregnancy_US = C legal_status = Rx-only routes_of_administration = Intravenous\n\n\n| bioavailability = 100% (IV only) elimination_half-life = 20 days (range:\n| 11â50 days)\n\n\n| CAS_number_Ref = CAS_number = 216974-75-3 ATC_prefix = L01 ATC_suffix =\n| XC07 DrugBank_Ref = DrugBank = BTD00087 UNII_Ref = UNII = 2S9ZZM9Q9V\n| KEGG_Ref = KEGG = D06409 ChEMBL_Ref = ChEMBL = 1201583 ChemSpiderID_Ref =\n| ChemSpiderID = NA\n\n\n| C=6638 | H=10160 | N=1720 | O=2108 | S=44 molecular_weight = approx. 149 kDa\n}} 'Bevacizumab' (trade name 'Avastin', Genentech/Roche) is an angiogenesis\ninhibitor, a drug that slows the growth of new blood vessels. It is licensed to\ntreat various cancers, including colorectal, lung, breast (outside the USA),\nglioblastoma (USA only), kidney and ovarian.\n\nBevacizumab is a humanized monoclonal antibody that inhibits vascular\nendothelial growth factor A (VEGF-A). VEGF-A is a chemical\nsignal that stimulates angiogenesis in a variety of diseases, especially in\ncancer. Bevacizumab was the first clinically available angiogenesis inhibitor in\nthe United States.\n\nBevacizumab was approved by the U.S. Food and Drug Administration (FDA) for\ncertain metastatic cancers. It received its first approval in 2004, for\ncombination use with standard chemotherapy for metastatic colon cancer. http://www.gene.com/gene/products/information/pdf/avastin-\nprescribing.pdf It has since been approved for use in certain lung\ncancers, renal cancers, and glioblastoma multiforme of the brain.\n\nAt one point bevacizumab was approved for breast cancer by the FDA, but the\napproval was revoked on . The\napproval for breast cancer was revoked because, although there was evidence that\nit slowed progression of metastatic breast cancer, there was no evidence that it\nextended life or improved quality of life, and it caused adverse effects\nincluding severe high blood pressure and hemorrhaging. In 2008, the FDA gave\nbevacizumab provisional approval for metastatic breast cancer, subject to\nfurther studies. The FDA's advisory panel had recommended against approval. In July 2010, after new studies failed to show a\nsignificant benefit, the FDA's advisory panel recommended against the indication\nfor advanced breast cancer. Genentech requested a hearing, which was granted in\nJune 2011. The FDA ruled to withdraw the breast cancer indication in November\n2011. FDA approval is required for Genentech to market a drug for that\nindication. Doctors may sometimes prescribe it for that indication, although\ninsurance companies are less likely to pay for it. The drug\nremains approved for breast cancer use in other countries including\nAustralia.\n\nClinical trials are underway for many other indications including ovarian\ncancer, pediatric osteosarcoma, and certain non-malignant eye diseases. In the\ncurative setting (adjuvant therapy), clinical studies are underway in breast\ncancer and lung cancer.\n","linknr":739,"url":"avastin","recorded":1364123056,"links":["/w/index.php?title=Bevacizumab&action=edit","/w/index.php?title=Bevacizumab&action=edit","//en.wikipedia.org/apple-touch-icon.png","//bits.wikimedia.org/favicon/wikipedia.ico","/w/opensearch_desc.php","//en.wikipedia.org/w/api.php?action=rsd","//creativecommons.org/licenses/by-sa/3.0/","/w/index.php?title=Special:RecentChanges&feed=atom","/wiki/Bevacizumab","//bits.wikimedia.org/en.wikipedia.org/load.php?debug=false&lang=en&modules=ext.gadget.DRN-wizard%2CReferenceTooltips%2Ccharinsert%2Cteahouse%7Cext.wikihiero%7Cmediawiki.legacy.commonPrint%2Cshared%7Cmw.PopUpMediaTransform%7Cskins.vector&only=styles&skin=vector&*","//bits.wikimedia.org/en.wikipedia.org/load.php?debug=false&lang=en&modules=site&only=styles&skin=vector&*","//bits.wikimedia.org/en.wikipedia.org/load.php?debug=false&lang=en&modules=startup&only=scripts&skin=vector&*","//bits.wikimedia.org/geoiplookup","//meta.wikimedia.org","/w/index.php?title=Avastin&redirect=no","#mw-head","#p-search","/wiki/Nomenclature_of_monoclonal_antibodies","/wiki/Monoclonal_antibody#Applications","/wiki/File:Engineered_monoclonal_antibodies.svg","/wiki/Monoclonal_antibody#Production","/wiki/Humanized","/wiki/Mouse","/wiki/Antigen","/wiki/Vascular_endothelial_growth_factor_A","/wiki/Trade_name","/wiki/American_Society_of_Health-System_Pharmacists","/wiki/Drugs.com","http://www.drugs.com/monograph/bevacizumab.html","/wiki/Regulation_of_therapeutic_goods","/wiki/European_Medicines_Agency","http://www.ema.europa.eu/ema/index.jsp?curl=/pages/medicines/landing/epar_search.jsp&murl=menus/medicines/medicines.jsp&searchkwByEnter=true&status=Authorised&keyword=Avastin&searchType=Name&jsenabled=true","/wiki/U.S._Food_and_Drug_Administration","http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchTerm=Bevacizumab&SearchType=BasicSearch","/wiki/Pregnancy_category","/wiki/United_States","/wiki/Regulation_of_therapeutic_goods","/wiki/Route_of_administration","/wiki/Intravenous_therapy","/wiki/Bioavailability","/wiki/Biological_half-life","/wiki/CAS_registry_number","http://www.nlm.nih.gov/cgi/mesh/2009/MB_cgi?term=216974-75-3&rn=1","//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png","/wiki/Anatomical_Therapeutic_Chemical_Classification_System","/wiki/ATC_code_L01","http://www.whocc.no/atc_ddd_index/?code=L01XC07","/wiki/DrugBank","http://www.drugbank.ca/drugs/BTD00087","/wiki/Unique_Ingredient_Identifier","http://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=2S9ZZM9Q9V","//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png","/wiki/KEGG","http://www.kegg.jp/entry/D06409","//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png","/wiki/ChEMBL","https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL1201583","//upload.wikimedia.org/wikipedia/commons/thumb/a/a2/X_mark.svg/7px-X_mark.svg.png","/wiki/Chemical_formula","/wiki/Carbon","/wiki/Hydrogen","/wiki/Nitrogen","/wiki/Oxygen","/wiki/Sulfur","/wiki/Molecular_mass","/wiki/KDa","//upload.wikimedia.org/wikipedia/commons/thumb/a/a2/X_mark.svg/14px-X_mark.svg.png","/wiki/Wikipedia:WikiProject_Chemicals/Chembox_validation","//en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=477165031&page2=Bevacizumab","/wiki/Genentech","/wiki/Hoffmann%E2%80%93La_Roche","/wiki/Angiogenesis_inhibitor","/wiki/Angiogenesis","/wiki/Monoclonal_antibody","/wiki/Vascular_endothelial_growth_factor_A","#cite_note-Los-1","/wiki/Cancer","/wiki/Angiogenesis_inhibitor","/wiki/Wikipedia:Citation_needed","/wiki/Food_and_Drug_Administration_(United_States)","/wiki/Metastasis","/wiki/Chemotherapy","/wiki/Colon_cancer","#cite_note-2","/wiki/Glioblastoma_multiforme","/wiki/Breast_cancer","#cite_note-NYT2011-3","#cite_note-bbc-4","#cite_note-nytimesref-5","#cite_note-NYT2011-3","#cite_note-6","/wiki/Adjuvant_therapy","#Background","#Indications","#Colorectal_cancer","#Lung_cancer","#Breast_cancer","#History_relating_to_breast_cancer","#Renal_cancers","#Brain_cancers","#Investigational_uses","#Uses_in_eye_disease","#Drug_administration","#Concerns","#Adverse_effects","#Costs","#Counterfeit","#See_also","#References","#External_links","/w/index.php?title=Bevacizumab&action=edit&section=1","/wiki/Vascular_endothelial_growth_factor","/w/index.php?title=Bevacizumab&action=edit&section=2","/w/index.php?title=Bevacizumab&action=edit&section=3","/wiki/Colorectal_cancer","#cite_note-7","/wiki/European_Medicines_Agency","/wiki/Colorectal_cancer","/wiki/Wikipedia:Citation_needed","/w/index.php?title=Bevacizumab&action=edit&section=4","/w/index.php?title=Bevacizumab&action=edit&section=5","#cite_note-FDA_breast1-8","#cite_note-Breast_Cancer-9","#cite_note-scijul11-10","/wiki/Food_and_Drug_Administration","#cite_note-11","/w/index.php?title=Bevacizumab&action=edit&section=6","/wiki/Wikipedia:Citation_needed","/wiki/Breast_cancer","/wiki/Cancer","/wiki/Clinical_trial","/wiki/Progression_Free_Survival","/wiki/Pharmaceutical_companies","#cite_note-nytimesref-5","/wiki/Paclitaxel","#cite_note-Austria-Codex-12","/w/index.php?title=Bevacizumab&action=edit&section=7","/wiki/Renal_cell_carcinoma","/wiki/Kidney_cancer","#cite_note-13","#cite_note-14","#cite_note-15","/wiki/Wikipedia:Citation_needed","/w/index.php?title=Bevacizumab&action=edit&section=8","/wiki/Glioblastoma_multiforme","#cite_note-16","#cite_note-17","/wiki/Journal_of_Clinical_Oncology","/wiki/UCLA","/wiki/Glioblastoma","#cite_note-18","/wiki/John_A._Boockvar","/wiki/Weill_Cornell_Medical_College","/wiki/Glioblastoma_multiforme","#cite_note-BBB-19","/w/index.php?title=Bevacizumab&action=edit&section=9","/wiki/Wikipedia:Citation_needed","#cite_note-20","/wiki/Ovarian_cancer","#cite_note-21","#cite_note-22","/wiki/Glioblastoma_multiforme","#cite_note-23","/wiki/Progression-free_survival","/wiki/Ovarian_cancer","#cite_note-24","/wiki/Pancreatic_cancer","#cite_note-25","#cite_note-26","#cite_note-27","#cite_note-28","/w/index.php?title=Bevacizumab&action=edit&section=10","/wiki/Age-related_macular_degeneration","/wiki/Diabetic_retinopathy","/wiki/Retina","/wiki/Off-label_use","/wiki/Vitreous_humour","/wiki/Choroidal_neovascularization","#cite_note-29","/wiki/Diabetic_retinopathy","/wiki/Neovascular_glaucoma","/wiki/Macular_edema","/wiki/Retinopathy_of_prematurity","#cite_note-30","/wiki/Ranibizumab","/wiki/Fragment_antigen_binding","/wiki/Napoleone_Ferrara","/wiki/Wikipedia:Avoid_weasel_words","/wiki/Choroidal_neovascularization","/wiki/Wikipedia:Citation_needed","#cite_note-31","#cite_note-32","/wiki/Area_under_the_curve","/wiki/National_Eye_Institute","/wiki/National_Institutes_of_Health","#cite_note-33","#cite_note-34","#cite_note-35","/wiki/New_England_Journal_of_Medicine","#cite_note-36","#cite_note-37","/w/index.php?title=Bevacizumab&action=edit&section=11","/wiki/5-fluorouracil","/wiki/Leucovorin","/wiki/Oxaliplatin","/wiki/Irinotecan","/wiki/Wikipedia:Citation_needed","#cite_note-BBB-19","#cite_note-38","/w/index.php?title=Bevacizumab&action=edit&section=12","/w/index.php?title=Bevacizumab&action=edit&section=13","/wiki/Wound_healing","/wiki/Collateral_circulation","/wiki/Atherosclerosis","/wiki/Coronary_artery_disease","/wiki/Peripheral_artery_disease","#cite_note-39","/wiki/Hypertension","/wiki/Bleeding","/wiki/Bowel_perforation","#cite_note-40","#cite_note-41","#cite_note-42","/wiki/Nasal_septum_perforation","/wiki/Thrombotic_microangiopathy","#cite_note-43","/wiki/Ophthalmology","/wiki/Wikipedia:Citation_needed","/w/index.php?title=Bevacizumab&action=edit&section=14","/wiki/Wikipedia:Citation_needed","/wiki/Wikipedia:Citation_needed","/wiki/National_Institute_for_Health_and_Clinical_Excellence","#cite_note-BBCReport-44","/wiki/Quality-adjusted_life_year","#cite_note-45","/wiki/Wikipedia:Citation_needed","#cite_note-46","/wiki/Colorectal_cancer","/wiki/New_England_Journal_of_Medicine","#cite_note-47","#cite_note-48","/w/index.php?title=Bevacizumab&action=edit&section=15","#cite_note-49","/wiki/Salt","/wiki/Starch","/wiki/Citrate","/wiki/Isopropanol","/wiki/Propanediol","/wiki/T-butanol","/wiki/Benzoic_acid","/wiki/Acetone","/wiki/Phthalate","#cite_note-50","#cite_note-51","/w/index.php?title=Bevacizumab&action=edit&section=16","/wiki/Angiogenesis","/wiki/Angiogenesis_inhibitor","/wiki/Colorectal_cancer","/wiki/Glioblastoma_multiforme","/wiki/Metastatic_breast_cancer","/wiki/Renal_cell_carcinoma","/wiki/Vascular_endothelial_growth_factor","/w/index.php?title=Bevacizumab&action=edit&section=17","#cite_ref-Los_1-0","/wiki/Digital_object_identifier","http://dx.doi.org/10.1634%2Ftheoncologist.12-4-443","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/17470687","#cite_ref-2","http://www.gene.com/gene/products/information/pdf/avastin-prescribing.pdf","#cite_ref-NYT2011_3-0","#cite_ref-NYT2011_3-1","http://prescriptions.blogs.nytimes.com/2011/11/18/f-d-a-revokes-approval-of-avastin-for-breast-cancer/","http://prescriptions.blogs.nytimes.com/2011/11/18/f-d-a-revokes-approval-of-avastin-for-breast-cancer/","#cite_ref-bbc_4-0","http://www.bbc.co.uk/news/world-us-canada-15800907","/wiki/BBC","http://www.bbc.co.uk/news/world-us-canada-15800907","#cite_ref-nytimesref_5-0","#cite_ref-nytimesref_5-1","http://www.nytimes.com/2008/02/22/business/apee-drug.html","/wiki/The_New_York_Times","http://www.nytimes.com/2008/02/22/business/apee-drug.html","#cite_ref-6","http://www.abc.net.au/news/stories/2010/07/22/2960728.htm","http://www.abc.net.au/news/stories/2010/07/22/2960728.htm","#cite_ref-7","http://jco.ascopubs.org/content/29/1/1.full","http://jco.ascopubs.org/content/29/1/1.full","#cite_ref-FDA_breast1_8-0","http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm237172.htm","http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm237172.htm","#cite_ref-Breast_Cancer_9-0","http://www.nytimes.com/2010/12/17/health/policy/17drug.html","http://www.nytimes.com/2010/12/17/health/policy/17drug.html","#cite_ref-scijul11_10-0","/wiki/Digital_object_identifier","http://dx.doi.org/10.1126%2Fscience.333.6039.143","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/21737712","#cite_ref-11","http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm280536.htm","http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm280536.htm","#cite_ref-Austria-Codex_12-0","/wiki/International_Standard_Book_Number","/wiki/Special:BookSources/978-3-85200-181-4","/wiki/Wikipedia:Citing_sources","#cite_ref-13","http://www.sfgate.com/cgi-bin/article.cgi?f=/n/a/2009/08/02/financial/f190253D65.DTL","http://www.sfgate.com/cgi-bin/article.cgi?f=/n/a/2009/08/02/financial/f190253D65.DTL","#cite_ref-14","http://www.genengnews.com/news/bnitem.aspx?name=59562374","http://www.genengnews.com/news/bnitem.aspx?name=59562374","#cite_ref-15","/wiki/Digital_object_identifier","http://dx.doi.org/10.1158%2F1078-0432.CCR-06-1989","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/17317817","#cite_ref-16","http://www.cancer.gov/cancertopics/druginfo/fda-bevacizumab#Anchor-Glioblastoma","http://www.cancer.gov/cancertopics/druginfo/fda-bevacizumab#Anchor-Glioblastoma","#cite_ref-17","http://www.marketwatch.com/story/fda-grants-accelerated-approval-of-avastin-for-brain-cancer-glioblastoma-that-has-progressed-following-prior-therapy","http://www.marketwatch.com/story/fda-grants-accelerated-approval-of-avastin-for-brain-cancer-glioblastoma-that-has-progressed-following-prior-therapy","#cite_ref-18","http://www.oncogenetics.org/web/avastin-dramatically-improves-response-survival-in-deadly-recurrrent-glioblastomas","http://www.oncogenetics.org/web/avastin-dramatically-improves-response-survival-in-deadly-recurrrent-glioblastomas","/wiki/Wikipedia:Link_rot","#cite_ref-BBB_19-0","#cite_ref-BBB_19-1","http://linkinghub.elsevier.com/retrieve/pii/S1878-8750(11)00691-7","/wiki/Digital_object_identifier","http://dx.doi.org/10.1016%2Fj.wneu.2011.05.056","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/22405392","http://linkinghub.elsevier.com/retrieve/pii/S1878-8750(11)00691-7","#cite_ref-20","http://www.reuters.com/article/euRegulatoryNews/idUSLM27429520090422","http://www.reuters.com/article/euRegulatoryNews/idUSLM27429520090422","#cite_ref-21","http://www.asco.org/ASCO/Abstracts+&+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=47&abstractID=31096","#cite_ref-22","http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID=52788","#cite_ref-23","http://meeting.ascopubs.org/cgi/content/abstract/26/15_suppl/2010b","http://meeting.ascopubs.org/cgi/content/abstract/26/15_suppl/2010b","#cite_ref-24","http://www.genengnews.com/gen-news-highlights/roche-claims-phase-iii-data-supports-use-of-avastin-in-ovarian-cancer/81244051/","http://www.genengnews.com/gen-news-highlights/roche-claims-phase-iii-data-supports-use-of-avastin-in-ovarian-cancer/81244051/","#cite_ref-25","http://www.joplink.net/prev/200807/27.html","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/18648128","http://www.joplink.net/prev/200807/27.html","#cite_ref-26","/wiki/Digital_object_identifier","http://dx.doi.org/10.1097%2FCAD.0b013e3282fc9d11","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/18418211","#cite_ref-27","/wiki/Digital_object_identifier","http://dx.doi.org/10.1007%2F978-3-540-71279-4_14","/wiki/International_Standard_Book_Number","/wiki/Special:BookSources/978-3-540-71266-4","#cite_ref-28","http://www.wbaltv.com/health/23686741/detail.html","http://www.wbaltv.com/health/23686741/detail.html","#cite_ref-29","/wiki/Digital_object_identifier","http://dx.doi.org/10.1097%2FIAE.0b013e3181884ff4","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/18827735","#cite_ref-30","/wiki/Digital_object_identifier","http://dx.doi.org/10.4103%2F0301-4738.33057","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/17595491","#cite_ref-31","http://online.wsj.com/article/SB20001424052748703513604575311070894017154.html","http://online.wsj.com/article/SB20001424052748703513604575311070894017154.html","#cite_ref-32","/wiki/Digital_object_identifier","http://dx.doi.org/10.1136%2Fbmj.c2459","#cite_ref-33","http://clinicalstudies.info.nih.gov/cgi/wais/bold032001.pl?A_08-EI-0061.html","#cite_ref-34","http://irvaronsjournal.blogspot.com/2007/09/catt-study-update-3-avastin-vs-lucentis.html","/wiki/Wikipedia:Identifying_reliable_sources_(medicine)","#cite_ref-35","/wiki/ClinicalTrials.gov","http://www.clinicaltrials.gov/show/NCT00593450","#cite_ref-36","http://www.nejm.org/doi/full/10.1056/NEJMoa1102673#t=articleBackground","/wiki/Digital_object_identifier","http://dx.doi.org/10.1056%2FNEJMoa1102673","/wiki/PubMed_Central","//www.ncbi.nlm.nih.gov/pmc/articles/PMC3157322","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/21526923","http://www.nejm.org/doi/full/10.1056/NEJMoa1102673#t=articleBackground","#cite_ref-37","//www.ncbi.nlm.nih.gov/pmc/articles/PMC3389193/","/wiki/Digital_object_identifier","http://dx.doi.org/10.1016%2Fj.ophtha.2012.03.053","/wiki/PubMed_Central","//www.ncbi.nlm.nih.gov/pmc/articles/PMC3389193","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/22555112","http://en.wikipedia.org/w/index.php?title=Template:Cite_pmid/22555112&action=edit&editintro=Template:Cite_pmid/editintro2","#cite_ref-38","http://www.sawfnews.com/Health/61214.aspx","http://www.sawfnews.com/Health/61214.aspx","#cite_ref-39","http://www.nejm.org/doi/abs/10.1056/NEJMcibr0800272?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed","/wiki/Digital_object_identifier","http://dx.doi.org/10.1056%2FNEJMcibr0800272","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/18463385","http://www.nejm.org/doi/abs/10.1056/NEJMcibr0800272?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed","#cite_ref-40","http://www.ncbi.nlm.nih.gov/pubmed/21803880","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/21803880","http://www.ncbi.nlm.nih.gov/pubmed/21803880","#cite_ref-41","/wiki/Digital_object_identifier","http://dx.doi.org/10.1097%2F01243894-200606000-00023","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/17409907","#cite_ref-42","/wiki/Digital_object_identifier","http://dx.doi.org/10.1007%2Fs11912-008-0013-z","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/18366965","#cite_ref-43","//www.ncbi.nlm.nih.gov/pmc/articles/PMC3030578/","/wiki/Digital_object_identifier","http://dx.doi.org/10.1056%2FNEJMoa0707330","/wiki/PubMed_Central","//www.ncbi.nlm.nih.gov/pmc/articles/PMC3030578","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/18337603","#cite_ref-BBCReport_44-0","http://www.bbc.co.uk/news/health-11060968","http://www.bbc.co.uk/news/health-11060968","#cite_ref-45","http://www.scottishmedicines.org.uk/files/bevacizumab__Avastin__Resubmissionn_May_06_FINAL_for_website.pdf","http://www.scottishmedicines.org.uk/files/bevacizumab__Avastin__Resubmissionn_May_06_FINAL_for_website.pdf","#cite_ref-46","http://www.nytimes.com/2006/02/15/business/15drug.html","http://www.nytimes.com/2006/02/15/business/15drug.html","#cite_ref-47","/wiki/Digital_object_identifier","http://dx.doi.org/10.1056%2FNEJMe048098","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/15175443","#cite_ref-48","http://www.cbc.ca/canada/prince-edward-island/story/2009/11/26/pei-avastin-stein-currie-584.html","http://www.cbc.ca/canada/prince-edward-island/story/2009/11/26/pei-avastin-stein-currie-584.html","#cite_ref-49","http://www.reuters.com/article/2012/02/15/us-counterfeits-cancer-drug-avastin-foun-idUSTRE81E1TK20120215","http://www.reuters.com/article/2012/02/15/us-counterfeits-cancer-drug-avastin-foun-idUSTRE81E1TK20120215","#cite_ref-50","http://uk.reuters.com/article/2012/02/27/us-avastin-idUKTRE81Q29X20120227","http://uk.reuters.com/article/2012/02/27/us-avastin-idUKTRE81Q29X20120227","#cite_ref-51","http://www.fiercepharma.com/story/phony-avastin-vials-contained-chemicals-no-drugs/2012-02-28","http://www.fiercepharma.com/story/phony-avastin-vials-contained-chemicals-no-drugs/2012-02-28","/w/index.php?title=Bevacizumab&action=edit&section=18","http://www.avastin.com","http://www.amdsupport.ca/articles/55/1/Off-Label-Uses-of-Avastin-as-a-Treatment-for-Macular-Degeneration/Page1.html","http://www.avastin-info.com","http://insciences.org/articles.php?tag=Avastin","http://www.nytimes.com/2006/02/15/business/15drug.html?ex=1297659600&en=62aabaec5acffa8c&ei=5090&partner=rssuserland&emc=rss","/wiki/New_York_Times","http://www.nytimes.com/2006/02/15/business/15drug.html?ex=1297659600&en=62aabaec5acffa8c&ei=5090&partner=rssuserland&emc=rss","http://www.cancer.gov/cancertopics/druginfo/bevacizumab","http://www.cancer.gov/Templates/drugdictionary.aspx?CdrID=43234","/wiki/ClinicalTrials.gov","http://www.clinicaltrials.gov/show/NCT00222469","http://irvaronsjournal.blogspot.com/2007/09/catt-study-update-3-avastin-vs-lucentis.html","/wiki/ClinicalTrials.gov","http://www.clinicaltrials.gov/show/NCT00593450","http://linkinghub.elsevier.com/retrieve/pii/S1526-8209(11)70536-5","/wiki/Digital_object_identifier","http://dx.doi.org/10.3816%2FCBC.2008.n.048","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/18952553","http://linkinghub.elsevier.com/retrieve/pii/S1526-8209(11)70536-5","http://druginfo.nlm.nih.gov/drugportal/dpdirect.jsp?name=Bevacizumab","http://currentcancer.com/nccn-guidelines-for-breast-cancer-updated-bevacizumab-recommendation-affirmed.html","http://www.drugcite.com/?q=AVASTIN","/wiki/Template:Extracellular_chemotherapeutic_agents","/wiki/Template_talk:Extracellular_chemotherapeutic_agents","//en.wikipedia.org/w/index.php?title=Template:Extracellular_chemotherapeutic_agents&action=edit","/wiki/Targeted_therapy","/wiki/Chemotherapy_(oncology)","/wiki/Antineoplastic","/wiki/ATC_code_L01","/wiki/Cancer_immunotherapy","/wiki/Monoclonal_antibody_therapy","/wiki/Receptor_tyrosine_kinase","/wiki/ErbB","/wiki/Epidermal_growth_factor_receptor","/wiki/Cetuximab","/wiki/Panitumumab","/wiki/HER2/neu","/wiki/Trastuzumab","/wiki/Trastuzumab_emtansine","/wiki/EpCAM","/wiki/Catumaxomab","/wiki/Edrecolomab","/wiki/Vascular_endothelial_growth_factor_A","/wiki/Leukemia","/wiki/Lymphoma","/wiki/Lymphatic_system","/wiki/CD20","/wiki/Ibritumomab_tiuxetan","/wiki/Ofatumumab","/wiki/Rituximab","/wiki/Tositumomab","/wiki/CD30","/wiki/Brentuximab_vedotin","/wiki/CD52","/wiki/Alemtuzumab","/wiki/Myeloid","/wiki/CD33","/wiki/Gemtuzumab_ozogamicin","/wiki/Tyrosine-kinase_inhibitor","/wiki/Receptor_tyrosine_kinase","/wiki/ErbB","/wiki/Epidermal_growth_factor_receptor","/wiki/Erlotinib","/wiki/Gefitinib","/wiki/Vandetanib","/wiki/HER2/neu","/wiki/Afatinib","/wiki/Lapatinib","/wiki/Neratinib","/wiki/RTK_class_III","/wiki/CD117","/wiki/Platelet-derived_growth_factor_receptor","/wiki/Axitinib","/wiki/Masitinib","/wiki/Pazopanib","/wiki/Sunitinib","/wiki/Sorafenib","/wiki/Toceranib","/wiki/CD135","/wiki/Lestaurtinib","/wiki/VEGF_receptors","/wiki/Axitinib","/wiki/Cediranib","/wiki/Pazopanib","/wiki/Regorafenib","/wiki/Semaxanib","/wiki/Sorafenib","/wiki/Sunitinib","/wiki/Toceranib","/wiki/Vandetanib","/wiki/Non-receptor_tyrosine_kinase","/wiki/Bcr-abl_fusion_protein","/wiki/Imatinib","/wiki/Dasatinib","/wiki/Nilotinib","/wiki/Ponatinib","/wiki/Src_(gene)","/wiki/Bosutinib","/wiki/Janus_kinase","/wiki/Lestaurtinib","/wiki/Ruxolitinib","/wiki/EML4","/wiki/Anaplastic_lymphoma_kinase","/wiki/Crizotinib","/wiki/Vandetanib","/wiki/Cabozantinib","/wiki/Fusion_protein","/wiki/Vascular_endothelial_growth_factor","/wiki/Aflibercept","/wiki/Proapoptotic","/wiki/ANXA2","/wiki/Prohibitin","/wiki/Adipotide","/wiki/Exotoxin","/wiki/Interleukin_2","/wiki/Denileukin_diftitox","/wiki/MTOR_inhibitor","/wiki/Everolimus","/wiki/Temsirolimus","/wiki/Template:Medicine_navs","/wiki/Neoplasm","/wiki/Template:Tumor_suppressor_genes_and_oncogenes","/wiki/Template:Tumor_markers","/wiki/Template:Tumors","/wiki/Template:Eponymous_medical_signs_for_oncology","/wiki/Template:Paraneoplastic_syndromes","/wiki/ATC_code_L","/wiki/Template:Intracellular_chemotherapeutic_agents","/wiki/Template:Extracellular_chemotherapeutic_agents","/wiki/Template:Detoxifying_agents_for_antineoplastic_treatment","/wiki/Template:Monoclonals_for_bone,_musculoskeletal,_circulatory,_and_neurologic_systems","/wiki/Template_talk:Monoclonals_for_bone,_musculoskeletal,_circulatory,_and_neurologic_systems","//en.wikipedia.org/w/index.php?title=Template:Monoclonals_for_bone,_musculoskeletal,_circulatory,_and_neurologic_systems&action=edit","/wiki/Monoclonal","/wiki/Bone","/wiki/Denosumab","/wiki/Blosozumab","/wiki/Romosozumab","/wiki/Musculoskeletal","/wiki/Stamulumab","/wiki/Circulatory_system","/wiki/Alirocumab","/wiki/Enoticumab","/wiki/Icrucumab","/wiki/Inclacumab","/wiki/Nesvacumab","/wiki/Orticumab","/wiki/Ramucirumab","/wiki/Vesencumab","/wiki/Indium_(111In)_biciromab","/wiki/Indium_(111In)_imciromab","/wiki/Chimeric_antibody","/wiki/Abciximab","/wiki/Volociximab","/wiki/Humanized_antibody","/wiki/Alacizumab_pegol","/wiki/Ranibizumab","/wiki/Caplacizumab","/wiki/Demcizumab","/wiki/Etaracizumab","/wiki/Tadocizumab","/wiki/Neurologic","/wiki/Atinumab","/wiki/Fasinumab","/wiki/Fulranumab","/wiki/Gantenerumab","/wiki/Bapineuzumab","/wiki/Crenezumab","/wiki/Ozanezumab","/wiki/Ponezumab","/wiki/Solanezumab","/wiki/Tanezumab","/wiki/Angiogenesis_inhibitor","/wiki/Ranibizumab","/wiki/List_of_World_Health_Organization_Essential_Medicines","/wiki/List_of_withdrawn_drugs","/wiki/Clinical_trial","/wiki/Clinical_trial#Phase_III","/wiki/Clinical_trial#Phase_II","http://en.wikipedia.org/w/index.php?title=Bevacizumab&oldid=543956453","/wiki/Help:Categories","/wiki/Category:Angiogenesis_inhibitors","/wiki/Category:Monoclonal_antibodies_for_tumors","/wiki/Category:Orphan_drugs","/wiki/Category:Wikipedia_articles_needing_page_number_citations_from_July_2011","/wiki/Category:All_articles_with_dead_external_links","/wiki/Category:Articles_with_dead_external_links_from_October_2010","/wiki/Category:All_articles_lacking_reliable_references","/wiki/Category:Articles_lacking_reliable_references_from_July_2011","/wiki/Category:Chemical_compounds_which_do_not_have_a_ChemSpiderID","/wiki/Category:Articles_with_changed_EBI_identifier","/wiki/Category:Drugboxes_which_contain_changes_to_verified_fields","/wiki/Category:All_articles_with_unsourced_statements","/wiki/Category:Articles_with_unsourced_statements_from_August_2010","/wiki/Category:Articles_with_unsourced_statements_from_December_2010","/wiki/Category:Articles_with_unsourced_statements_from_July_2011","/wiki/Category:Articles_with_unsourced_statements_from_March_2012","/wiki/Category:All_articles_with_specifically_marked_weasel-worded_phrases","/wiki/Category:Articles_with_specifically_marked_weasel-worded_phrases_from_April_2012","/wiki/Category:Articles_with_unsourced_statements_from_June_2011","/w/index.php?title=Special:UserLogin&returnto=Bevacizumab&type=signup","/w/index.php?title=Special:UserLogin&returnto=Bevacizumab","/wiki/Bevacizumab","/wiki/Talk:Bevacizumab","#","/wiki/Bevacizumab","/w/index.php?title=Bevacizumab&action=edit","/w/index.php?title=Bevacizumab&action=history","#","/w/index.php","//bits.wikimedia.org/static-1.21wmf11/skins/vector/images/search-ltr.png?303-4","/wiki/Main_Page","/wiki/Main_Page","/wiki/Portal:Contents","/wiki/Portal:Featured_content","/wiki/Portal:Current_events","/wiki/Special:Random","//donate.wikimedia.org/wiki/Special:FundraiserRedirector?utm_source=donate&utm_medium=sidebar&utm_campaign=C13_en.wikipedia.org&uselang=en","/wiki/Help:Contents","/wiki/Wikipedia:About","/wiki/Wikipedia:Community_portal","/wiki/Special:RecentChanges","/wiki/Wikipedia:Contact_us","/wiki/Special:WhatLinksHere/Bevacizumab","/wiki/Special:RecentChangesLinked/Bevacizumab","/wiki/Wikipedia:File_Upload_Wizard","/wiki/Special:SpecialPages","/w/index.php?title=Bevacizumab&oldid=543956453","/w/index.php?title=Bevacizumab&action=info","/w/index.php?title=Special:Cite&page=Bevacizumab&id=543956453","/w/index.php?title=Special:Book&bookcmd=book_creator&referer=Bevacizumab","/w/index.php?title=Special:Book&bookcmd=render_article&arttitle=Bevacizumab&oldid=543956453&writer=rl","/w/index.php?title=Bevacizumab&printable=yes","//ar.wikipedia.org/wiki/%D8%A8%D9%8A%D9%81%D8%A7%D8%B3%D9%8A%D8%B2%D9%88%D9%85%D8%A7%D8%A8","//ca.wikipedia.org/wiki/Bevacizumab","//de.wikipedia.org/wiki/Bevacizumab","//es.wikipedia.org/wiki/Bevacizumab","//fr.wikipedia.org/wiki/B%C3%A9vacizumab","//hr.wikipedia.org/wiki/Bevacizumab","//it.wikipedia.org/wiki/Bevacizumab","//he.wikipedia.org/wiki/%D7%90%D7%95%D7%95%D7%A1%D7%98%D7%99%D7%9F","//nl.wikipedia.org/wiki/Bevacizumab","//ja.wikipedia.org/wiki/%E3%83%99%E3%83%90%E3%82%B7%E3%82%BA%E3%83%9E%E3%83%96","//pl.wikipedia.org/wiki/Bewacizumab","//pt.wikipedia.org/wiki/Bevacizumab","//ru.wikipedia.org/wiki/%D0%91%D0%B5%D0%B2%D0%B0%D1%86%D0%B8%D0%B7%D1%83%D0%BC%D0%B0%D0%B1","//simple.wikipedia.org/wiki/Bevacizumab","//sl.wikipedia.org/wiki/Bevacizumab","//sr.wikipedia.org/wiki/Bevacizumab","//sh.wikipedia.org/wiki/Bevacizumab","//fi.wikipedia.org/wiki/Bevasitsumabi","//tr.wikipedia.org/wiki/Bevacizumab","//zh.wikipedia.org/wiki/%E5%AE%89%E7%BB%B4%E6%B1%80","//www.wikidata.org/wiki/Special:ItemByTitle/enwiki/Bevacizumab","//en.wikipedia.org/wiki/Wikipedia:Text_of_Creative_Commons_Attribution-ShareAlike_3.0_Unported_License","//creativecommons.org/licenses/by-sa/3.0/","//wikimediafoundation.org/wiki/Terms_of_Use","//www.wikimediafoundation.org/","//en.wikipedia.org/wiki/Wikipedia:Contact_us","//wikimediafoundation.org/wiki/Privacy_policy","/wiki/Wikipedia:About","/wiki/Wikipedia:General_disclaimer","http://en.m.wikipedia.org/wiki/Bevacizumab","//wikimediafoundation.org/","//bits.wikimedia.org/images/wikimedia-button.png","//www.mediawiki.org/","//bits.wikimedia.org/static-1.21wmf11/skins/common/images/poweredby_mediawiki_88x31.png","//bits.wikimedia.org/en.wikipedia.org/load.php?debug=false&lang=en&modules=skins.vector&only=scripts&skin=vector&*","/w/index.php?title=MediaWiki:Gadget-ReferenceTooltips.js&action=raw&ctype=text/javascript&508635914","//bits.wikimedia.org/en.wikipedia.org/load.php?debug=false&lang=en&modules=site&only=scripts&skin=vector&*"],"instances":["united_states"],"pdf":["http://www.gene.com/gene/products/information/pdf/avastin-prescribing.pdf","http://www.scottishmedicines.org.uk/files/bevacizumab__Avastin__Resubmissionn_May_06_FINAL_for_website.pdf","http://www.scottishmedicines.org.uk/files/bevacizumab__Avastin__Resubmissionn_May_06_FINAL_for_website.pdf"],"categories":["Angiogenesis inhibitors","Monoclonal antibodies for tumors","Orphan drugs"],"headings":["Background","Indications","Drug administration","Concerns","Counterfeit","See also","References","External links"],"image":["//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png","//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png","//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png","//upload.wikimedia.org/wikipedia/commons/thumb/a/a2/X_mark.svg/7px-X_mark.svg.png","//upload.wikimedia.org/wikipedia/commons/thumb/a/a2/X_mark.svg/14px-X_mark.svg.png","//bits.wikimedia.org/static-1.21wmf11/skins/vector/images/search-ltr.png?303-4","//bits.wikimedia.org/images/wikimedia-button.png","//bits.wikimedia.org/static-1.21wmf11/skins/common/images/poweredby_mediawiki_88x31.png"],"tags":[["food_and_drug_administration","united_states"]],"members":["food_and_drug_administration"],"related":["Vascular_endothelial_growth_factor_A","Intravenous_therapy","KDa","Genentech","Hoffmann–La_Roche","Angiogenesis_inhibitor","Angiogenesis","Monoclonal_antibody","Vascular_endothelial_growth_factor_A","Cancer","Angiogenesis_inhibitor","Food_and_Drug_Administration_(United_States)","Metastasis","Chemotherapy","Colon_cancer","Glioblastoma_multiforme","Breast_cancer","Adjuvant_therapy","Vascular_endothelial_growth_factor","Colorectal_cancer","European_Medicines_Agency","Colorectal_cancer","Food_and_Drug_Administration","Breast_cancer","Cancer","Clinical_trial","Progression_Free_Survival","Pharmaceutical_companies","Paclitaxel","Renal_cell_carcinoma","Kidney_cancer","Glioblastoma_multiforme","Journal_of_Clinical_Oncology","UCLA","Glioblastoma","John_A._Boockvar","Weill_Cornell_Medical_College","Glioblastoma_multiforme","Ovarian_cancer","Glioblastoma_multiforme","Progression-free_survival","Ovarian_cancer","Pancreatic_cancer","Age-related_macular_degeneration","Diabetic_retinopathy","Retina","Off-label_use","Vitreous_humour","Choroidal_neovascularization","Diabetic_retinopathy","Neovascular_glaucoma","Macular_edema","Retinopathy_of_prematurity","Ranibizumab","Fragment_antigen_binding","Napoleone_Ferrara","Choroidal_neovascularization","Area_under_the_curve","National_Eye_Institute","National_Institutes_of_Health","5-fluorouracil","Leucovorin","Oxaliplatin","Irinotecan","Wound_healing","Collateral_circulation","Atherosclerosis","Coronary_artery_disease","Peripheral_artery_disease","Hypertension","Bleeding","Bowel_perforation","Nasal_septum_perforation","Thrombotic_microangiopathy","Ophthalmology","National_Institute_for_Health_and_Clinical_Excellence","Quality-adjusted_life_year","Colorectal_cancer","New_England_Journal_of_Medicine","Salt","Starch","Citrate","Isopropanol","Propanediol","T-butanol","Benzoic_acid","Acetone","Phthalate","Angiogenesis","Angiogenesis_inhibitor","Colorectal_cancer","Glioblastoma_multiforme","Metastatic_breast_cancer","Renal_cell_carcinoma","Vascular_endothelial_growth_factor"]}